Recently, several novel human polyomaviruses (HPyVs) have been detected. HPyV6, 7, 9 and 10 are not associated with any disease so far. Trichodysplasia spinulosa (TS)-associated polyomavirus (TSPyV) can cause the rare skin disease TS. We have evaluated cutaneous DNA prevalence and viral loads of five HPyVs in HIV-infected men compared to healthy male controls. 449 forehead swabs were analysed by HPyV-specific real-time PCR. HPyV6, HPyV7, TSPyV and HPyV10 were found significantly more frequently on the skin of 210 HIV-infected compared to 239 HIV-negative men (HPyV6, 39.0 vs 27.6 %; HPyV7, 21.0 vs 13.4 %; TSPyV, 3.8 vs 0.8 %; HPyV10, 9.3 vs 3.4 %; P,0.05, respectively). HPyV9 was not detected. Multiple infections were more frequent in HIV-positive men, but HPyV-DNA loads did not differ significantly in both groups. In contrast to HPyV6, 7 and 10, TSPyV and HPyV9 do not seem to be a regular part of the human skin microbiome.
Polyomaviruses (PyVs) are small, non-enveloped doublestranded DNA viruses. Infections with the long-known human polyomaviruses (HPyVs) BKPyV and JCPyV are usually asymptomatic, but immunosuppression can lead to reactivation associated with serious diseases such as BKPyV-induced nephropathy or JCPyV-induced leukoencephalopathy (reviewed by Dalianis & Hirsch, 2013) . Recently, several novel HPyVs have been detected, with two of them being associated with human disease (reviewed by Ehlers & Wieland, 2013; Feltkamp et al., 2013; Rinaldo & Hirsch, 2013) : Merkel cell polyomavirus (MCPyV) is frequently integrated in Merkel cell carcinoma (MCC), a rare neuroectodermal tumour of the skin (Feng et al., 2008) . Trichodysplasia spinulosa-associated polyomavirus (TSPyV) was discovered in skin lesions of immunosuppressed patients with the rare disease trichodysplasia spinulosa (TS) van der Meijden et al., 2010) . So far, HPyV6, HPyV7, HPyV9, HPyV10 (and its isolates MWPyV and MXPyV), Saint Louis PyV and HPyV12 are not associated with any disease, and it remains to be determined whether these emerging viruses play a pathogenic role in humans (Buck et al., 2012; Ehlers & Wieland, 2013; Feltkamp et al., 2013; Korup et al., 2013; Lim et al., 2013; Schowalter et al., 2010; Scuda et al., 2011; Siebrasse et al., 2012; Yu et al., 2012) . Many viruses such as human papillomaviruses (HPVs) or Kaposi sarcomaassociated herpesvirus are more prevalent or persistent in HIV-infected individuals and the associated diseases are more abundant than in immunocompetent persons (Kreuter & Wieland, 2009) . Recently, we have found MCPyV more frequently on the skin of HIV-infected individuals compared to healthy controls, possibly explaining the increased risk for MCC in this patient group (Wieland et al., 2011) . The aim of the present study was to evaluate whether HPyV6, 7, 9, 10 and TSPyV occur more frequently on the skin of HIV-infected men compared to healthy controls. This could help to elucidate whether these novel HPyVs possibly play a role in skin diseases occurring more commonly in immunocompromised patients such as HIV-positive patients.
Forehead swabs (n5449) from 210 HIV-positive men and 239 healthy male controls were analysed in five quantitative type-specific real-time PCR (q-PCR) experiments for the presence of HPyV6, 7, 9, 10 and TSPyV. Characteristics of HIV-positive patients (median age 43 years, interquartile range (IQR) 11) and healthy male controls (median age 48, IQR 21) have been described in detail (Wieland et al., 2011) . The controls were healthy men seen for skin cancer screening. All 449 participants were Caucasians from Germany and were free of skin cancer, skin infections and acute or chronic inflammatory dermatoses. For HPyV10 analyses, only 443 samples from 205 HIV-positive men and 238 healthy male controls were available. The ethics review board of the Ruhr University Bochum approved the study and written informed consent was obtained from all participants (Wieland et al., 2011) .
Sample collection (forehead swabs covering about 10 cm 2 ) and DNA isolation (QIAamp DNA Mini; Qiagen) have been described previously (Wieland et al., 2011) . q-PCRs were run in 20 ml with LightCycler 480 Probes Master (Roche), 0.2 mM of each primer (TIB Molbiol), 0.1 mM locked nucleic acid probes (Roche) ( Table 1 ) and 2 ml extracted DNA on a LightCycler 480 (Roche). Cycling conditions were 10 min denaturation (95 u C) followed by 45 cycles at 95 u C for 10 s, 60 u C for 30 s and 72 u C for 5 s. Negative controls (water and human control DNA instead of patient samples) were included in each run and never yielded fluorescence signals above background. The analytical sensitivity of each assay was 10 copies of HPyV6, 7, 9, 10 or TSPyV standard-plasmid DNA (Buck et al., 2012; Schowalter et al., 2010; Scuda et al., 2011; van der Meijden et al., 2010) . Cross-reactivity was excluded by the addition of 10 000 and 1 000 000 copies of plasmid DNA of BKPyV, JCPyV, KIPyV, MCPyV, TSPyV, HPyV6, 7, 9, 10, respectively. Furthermore, the presence of the respective HPyV was confirmed by sequencing 10 HPyV6-, 10 HPyV7-, five TSPyV-and seven HPyV10-positive swabs. Human papillomavirus type 8 (HPV8), a prevalent cutaneous beta-papillomavirus that was originally associated with the rare genodermatosis epidermodysplasia verruciformis and that has a potential role in nonmelanoma skin cancer development, was analysed by q-PCR for comparison (Neale et al., 2013; Weissenborn et al., 2010) . The single copy beta-globin gene was quantified as previously described (Weissenborn et al., 2010; Wieland et al., 2011) . Viral loads were expressed as viral DNAcopies per beta-globin gene copy.
Qualitative data were cross-tabulated and tested for association by Pearson's chi-squared test (two-sided). Distributions of HPyV-DNA load as well as multiplicity of HPyV infections were tested for difference in location using the non-parametric Mann-Whitney U test for two independent samples. P values ,0.05 were considered statistically significant. Statistical analyses were done using IBM SPSS Statistics 20.
HPyV6, HPyV7, TSPyV and HPyV10 DNA was detected in 39.0 %, 21.0 %, 3.8 % and 9.3 % of forehead skin swabs of HIV-positive men, compared with 27.6 %, 13.4 %, 0.8 % and 3.4 % in healthy controls (P,0.05, respectively; Table  2 ). For HPV8, the difference between the two groups (11.4 % vs 7.1 %) did not reach significance (Table 2) . HPyV9 DNA could not be detected in any of the samples. Concomitant infections with more than one of the Similar to beta-HPV and MCPyV, HPyV6 and (to a lesser extent) HPyV7 are regularly found on normal skin (Antonsson et al., 2000; Foulongne et al., 2010 Foulongne et al., , 2012 Moens et al., 2011; Schowalter et al., 2010) . To our knowledge, data on HPyV6, HPyV7, TSPyV, HPyV9 and HPyV10 in HIV-positive patients have not been published. Here, HPyV6, HPyV7, TSPyV and HPyV10, as measured by viral DNA detection in skin swabs, were found significantly more frequently in HIV-infected men than in HIV-negative healthy controls. The HPyV-DNA detection rates found in our study for healthy controls are basically in line with previous studies: HPyV6 and HPyV7 were found in 14 % and 11 % of 35 healthy volunteers, respectively (Schowalter et al., 2010) . A high-throughput sequencing analysis of six normal forehead skin swabs revealed HPyV6 in three and HPyV7 in one of six samples (Foulongne et al., 2012) . TSPyV-DNA was detected in low copy numbers in 2.4 % (6/249) of forehead swabs of uninvolved skin (Kazem et al., 2012) . This was slightly more frequent than in our study (0.8 %; 2/239), but the difference was not significant (P50.171). Moreover, the two control groups differed in two aspects: the controls examined by Kazem et al. (age 4-79 years) also included children, while our controls comprised only adults (18-79 years); the controls in the study of Kazem et al. took part in a clinical trial on treatment of skin warts, while our controls were free of skin lesions. HPyV9 was originally discovered in blood and urine of immunosuppressed patients (Scuda et al., 2011) . In subsequent studies, HPyV9 DNA was found in one of the above-mentioned swabs analysed by high-throughput sequencing and in one of 111 skin swabs of healthy volunteers and non-MCC patients (Foulongne et al., 2012; Sauvage et al., 2011) . Thus, TSPyV and HPyV9 do not seem to be frequent components of the human skin microbiome. In contrast, TSPyV and HPyV9 antibodies have been detected in 67-91 % and in 33-70 % of adults, respectively, and primary infection seems to occur at a young age (Chen et al., 2011; Nicol et al., 2012 Nicol et al., , 2013 Sadeghi et al., 2012; Trusch et al., 2012; van der Meijden et al., 2011) . This could indicate that cutaneous re-exposure or reactivation of TSPyV and HPyV9 does not occur frequently, or that the skin is not the primary site of reactivation/persistence. HPyV10 was originally isolated from an HPV6-positive anal condyloma (wart) and its closely related variants MWPyV and MXPyV have been found in low frequencies in stool and respiratory samples without association with disease (Buck et al., 2012; Rockett et al., 2013; Siebrasse et al., 2012; Yu et al., 2012) . Studies on HPyV10 in skin samples have not been published so far. In contrast to the investigated HPyV and to MCPyV (Wieland et al., 2011) , HPV8 could not be detected significantly more often in HIV-positive patients. Cutaneous HPyV prevalence or clearance might be more apparently affected by HIV-induced immunosuppression than that of beta-papillomaviruses.
As previously shown for MCPyV (Wieland et al., 2011) , the viral loads of the analysed polyomaviruses did not differ significantly in HIV-positive and HIV-negative men. When looking at HPyV loads of HIV-positive men with well-and poorly controlled HIV infection, the latter had higher peak HPyV6 loads, but the difference was not significant, in contrast to MCPyV (Wieland et al., 2011) . The majority (81 %) of the HIV-patients in this study received ART (Wieland et al., 2011) . Possibly, HPyV load differences between HIV-positive and HIV-negative individuals would become apparent without the immune-reconstituting effect of ART.
Of the five polyomaviruses analysed here, only TSPyV is associated with a disease. TS is a rare skin disease (26 published cases) that has been seen in a few solid-organ transplant recipients, lymphocytic leukaemia patients, and very recently in a patient with the autoimmune disease lupus erythematosus Moktefi et al., 2013) . It is characterized by follicular keratotic papules and spicules, especially in the face (Haycox et al., 1999; van der Meijden et al., 2010) . To our knowledge, TS has never been described in HIV-positive patients . Possibly, the type or degree of immunosuppression found in (antiretrovirally treated) HIV-infected individuals does not allow the extensive TSPyV replication (to approximately 10 6 copies cell
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) described for TS (Kazem et al., 2012) . The maximum TSPyV load found in our HIVpositive men was six TSPyV copies per beta-globin gene copy. It could make sense to look for signs of TS in HIVinfected patients with advanced immunosuppression or in settings where ART is not readily available.
The major limitations of our study are that only one swab was collected from each participant and that only one skin site, the forehead, was investigated. Possibly, cutaneous HPyVs would have been detected in more individuals if consecutive swabs from more body sites had been collected.
In summary, the recently discovered HPyV6, HPyV7, TSPyV and HPyV10 are more frequently detected on the skin of HIV-positive men compared to healthy individuals. Future studies should investigate if these novel polyomaviruses possibly play a role in skin diseases occurring more often in HIV-positive patients, such as eosinophilic folliculitis or pruritic papular eruption.
